Change in Management
ALBERTDAVD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Albert David Ltd appointed Mr. Amit Mahla as CEO effective May 12, 2026. The appointment follows the resignation of Mr. Umesh Manohar Kunte from Managing Director & CEO post, effective December 18, 2025 (disclosed now). Mr. Mahla brings 28+ years of pharma experience from companies including JB Pharma, Sun Pharma, and Cipla. FY26 full-year results show revenue of Rs. 33,360 Lacs (vs Rs. 34,577 Lacs in FY25) and a net loss of Rs. 149 Lacs versus profit of Rs. 1,720 Lacs in prior year. The Q4 standalone quarter also recorded a loss of Rs. 2,143 Lacs. The board recommended a final dividend of Rs. 5 per share (50%), subject to shareholder approval at the August 6, 2026 AGM. Statutory auditors L.B. Jha & Co. issued an unmodified opinion.
The new CEO appointment from outside the company signals a potential strategic reset, though the significant FY26 loss and revenue decline may weigh on investor sentiment near-term. The dividend offer provides some investor relief.